Alternatively, Qureshi et al. (32) report a VTE incidence of 3.2% in patients with ALL who received treatment based on the UK ALL 2003 study, during a period of asparaginase depletion with no subsequent thrombosis during asparaginase re-challenges; 34 of 59 children received secondary anticoagulant prophylaxis. This evidence concerns the gene ASPG and Venous thrombosis.